Bibliographical noteFunding Information:
Kyriakie Sarafoglou receives research support from the Office of Orphan Products Development of the Food and Drug Administration (R01FDR0006100), Neurocrine Biosciences, Spruce Biosciences, and Adrenas Therapeutics; serves on the scientific advisory board for Eton Pharmaceuticals; and serves as a consultant for Neurocrine Biosciences and Spruce Biosciences on behalf of the University of Minnesota Medical School but does not receive personal income for these activities. Bradley S. Miller is a consultant for Abbvie, Ascendis Pharma, BioMarin, Bristol Myers Squibb, EMD Serono, Endo Pharmaceuticals, Novo Nordisk, Orchard Therapeutics, Pfizer, Tolmar, and Vertice and has received research support from Alexion, Abbvie, Aeterna Zentaris, Amgen, Amicus, Lumos Pharma, Lysogene, Novo Nordisk, OPKO Health Pfizer, Prevail Therapeutics, and Sangamo Therapeutics. Richard C. Brundage receives research support from the Office of Orphan Products Development of the Food and Drug Administration (R01FDR0006100). The rest of the authors have no disclosures to declare.
PubMed: MeSH publication types